Exelixis (EXEL) 2026 stock analysis: the Cabometyx (cabozantinib) franchise cash flow, Ipsen and Takeda royalties, the zanzalintinib next-gen pipeline, patent-cliff and generic-entry timing, and a buyback-first capital allocation strategy explained.
LigaChem Biosciences (KRX 141080, formerly LegoChem) stock outlook 2026: how its ADC ConjuAll linker platform, big-pharma license-out deals with partners like J&J, and Orion Group backing weigh against clinical, partner-dependency and valuation risks.
McKesson (NYSE: MCK) is a Big Three pharmaceutical distributor with a dominant logistics moat, aggressive buybacks, and a growing oncology network. Here's the honest 2026 investment case — bull, bear, and base.
AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.